Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model.
Studies showed that specific probiotics might provide therapeutic benefits in inflammatory bowel disease. However, a rigorous screening of new probiotics is needed to study possible adverse interactions with the host, particularly when intended for administration to individuals with certain health risks. In this context, the objective of this study was to investigate the role of three lactobacilli (LAB) on intestinal inflammation and bacterial translocation using variations of the mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced acute colitis. We first compared the in vitro ability of LAB to survive gastrointestinal tract (GIT) conditions and their ability to persist in the GIT of mice following daily oral administration. As a control, we included a nonprobiotic Lactobacillus paracasei strain, previously isolated from an endocarditis patient. Feeding high doses of LAB strains to healthy and to TNBS-treated mice did not induce any detrimental effect or abnormal translocation of the bacteria. Oral administration of Lactobacillus salivarius Ls-33 had a significant preventive effect on colitis in mice, while Lactobacillus plantarum Lp-115 and Lactobacillus acidophilus NCFM did not. None of the three selected LAB strains translocated to extraintestinal organs of TNBS-treated mice. In contrast, L. paracasei exacerbated colitis under severe inflammatory conditions and translocated to extraintestinal organs. This study showed that evaluations of the safety and functionality of new probiotics are recommended. We conclude that not all lactobacilli have similar effects on intestinal inflammation and that selected probiotics such as L. salivarius Ls-33 may be considered in the prevention or treatment of intestinal inflammation.
Daniel
Catherine
C
Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Pasteur de Lille, 59019 Lille Cedex, France. catherine.daniel@ibl.fr
Poiret
Sabine
S
Goudercourt
Denise
D
Dennin
Veronique
V
Leyer
Gregory
G
Pot
Bruno
B
D000208:Acute Disease; D000818:Animals; D001422:Bacterial Adhesion; D018938:Caco-2 Cells; D003092:Colitis / Q000139:chemically induced / Q000382:microbiology / Q000628:therapy*; D004195:Disease Models, Animal; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D066298:In Vitro Techniques; D007778:Lactobacillus / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000627:therapeutic use*; D012449:Safety; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
D014302:Trinitrobenzenesulfonic Acid